Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
clinical trials
deals
fda
5
×
investing
5
×
life sciences
national blog main
national top stories
roche
5
×
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
takeda pharmaceutical
texas blog main
texas top stories
vertex pharmaceuticals
wisconsin blog main
wisconsin top stories
boston
cancer immunotherapy
crispr-cas9
cystic fibrosis
What
roundup
ahead
asco
bio
cancer
days
drug
fda
alliance
ambien
american
analytics
annual
approval
attendees
attention
biofourmis
biotech
blueprint
branded
bristol
buy
calls
camp’s
candidate
cash
changing
chicago
choices
city
clinical
color
combinations
commissioner
community’s
consumers
costly
counterweight
crispr
currently
Language
unset
Current search:
roche
×
investing
×
fda
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
